CD47 and metabolic disease: In metabolic diseases, CD47 fosters adipose tissue inflammation, hepatic steatosis, and kidney lipotoxicity, while inhibiting pancreatic β-cell insulin secretion, whereas inhibition improves metabolic homeostasis and glucose regulation in preclinical models [125].